-+ 0.00%
-+ 0.00%
-+ 0.00%

Dong-A ST's Topical Icotrokinra Reduces Inflammation in Preclinical Psoriasis Study

PUBT·10/26/2026 13:31:21
Listen to the news
Dong-A ST's Topical Icotrokinra Reduces Inflammation in Preclinical Psoriasis Study
  • Dong-A ST presented preclinical results for topical icotrokinra for psoriasis at AAPS PharmSci 360 2026, held Oct. 25-28 in New Orleans.
  • The optimized formulation penetrated the skin barrier and retained icotrokinra in targeted skin layers in ex vivo testing.
  • Animal studies showed reduced inflammation, with significant suppression of gene expression for key psoriasis-related inflammatory cytokines.
  • The findings support continued development as a topical drug candidate, but clinical safety and efficacy require further study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A ST Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260930BIZWIRE_USPR_____20261026_BW151553) on October 26, 2026, and is solely responsible for the information contained therein.